Literature DB >> 29162389

Is cryptogenic cirrhosis different from NASH cirrhosis?

Paul J Thuluvath1, Sergey Kantsevoy2, Avesh J Thuluvath3, Yulia Savva4.   

Abstract

BACKGROUND & AIMS: We hypothesized that patients currently diagnosed with cryptogenic cirrhosis (CC) have truly 'cryptogenic' liver disease, which is unlikely to have evolved from NASH. The aim of this study is to characterize patients with CC, and compare their characteristics to patients with cirrhosis of other etiologies.
METHODS: To investigate this, we compared the clinical characteristics of adults with CC (n = 7,999) to those with cirrhosis caused by non-alcoholic steatohepatitis (NASH) (n = 11,302), alcohol (n = 21,714) and autoimmune hepatitis (n = 3,447), using the UNOS database from 2002-16. We performed an age, gender and year of listing matched comparison of CC and NASH (n = 7,201 in each group), and also stratified patients by the presence of obesity or diabetes mellitus (DM).
RESULTS: From 2002 to 2016, patients listed with a diagnosis of NASH increased from about 1% to 16% while CC decreased from 8% to 4%. A logistic regression model using the entire United Network for Organ Sharing data (n = 138,021) suggested that the strongest predictors of NASH were type 2 DM, obesity, age ≥60 years, female gender and white race. Type 2 DM was more common in patients with NASH (53%) than those with CC (29%), alcoholic cirrhosis (16%) and autoimmune hepatitis (16%), and obesity was more common in NASH (65.3%) compared to the other three groups (33-42%). There were more white individuals (82.3%) in the NASH group and a lower prevalence of black, Hispanic and Asian individuals, compared to the other three groups. Hepatocellular carcinoma was more commonly seen in NASH (19% vs. 9-13% in the other groups) and this is not influenced by obesity and type 2 DM. The differences between CC and NASH remained unchanged even when two groups were matched for age, gender and year of listing, or when stratified by the presence or absence of obesity or type 2DM.
CONCLUSIONS: Based on risk perspectives, CC should not be equated with the term 'NASH cirrhosis'. LAY
SUMMARY: We hypothesized that cryptogenic cirrhosis is a distinct condition from cirrhosis caused by non-alcoholic steatohepatitis (NASH). By comparing cryptogenic cirrhosis with cirrhosis of other causes, we found clear clinical differences. Therefore, cryptogenic cirrhosis should not be considered the same as NASH cirrhosis. Further investigations are required to identify unknown causes of cirrhosis.
Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Age and gender matched; Alcoholic cirrhosis; Autoimmune hepatitis; UNOS

Mesh:

Year:  2017        PMID: 29162389     DOI: 10.1016/j.jhep.2017.11.018

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  14 in total

1.  Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis.

Authors:  Mario Masarone; Jacopo Troisi; Andrea Aglitti; Pietro Torre; Angelo Colucci; Marcello Dallio; Alessandro Federico; Clara Balsano; Marcello Persico
Journal:  Metabolomics       Date:  2021-01-16       Impact factor: 4.290

Review 2.  Undiagnosed liver diseases.

Authors:  Emily Gao; Julian Hercun; Theo Heller; Sílvia Vilarinho
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

3.  A Nationwide Study of Inpatient Admissions, Mortality, and Costs for Patients with Cirrhosis from 2005 to 2015 in the USA.

Authors:  Biyao Zou; Yee Hui Yeo; Donghak Jeong; Haesuk Park; Edward Sheen; Dong Hyun Lee; Linda Henry; Gabriel Garcia; Erik Ingelsson; Ramsey Cheung; Mindie H Nguyen
Journal:  Dig Dis Sci       Date:  2019-10-09       Impact factor: 3.199

4.  The uprising of metabolic dysfunction-associated fatty liver disease (MAFLD) in acute-on-chronic liver failure (ACLF).

Authors:  Kenneth I Zheng; Ming-Hua Zheng
Journal:  Hepatobiliary Surg Nutr       Date:  2021-12       Impact factor: 7.293

Review 5.  Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.

Authors:  Daniel Q Huang; Hashem B El-Serag; Rohit Loomba
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-12-21       Impact factor: 46.802

6.  Pernicious anemia associated with cryptogenic cirrhosis: Two case reports and a literature review.

Authors:  Xin Yan; Runping Gao; Yulin Hu; Jinglan Jin
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.889

7.  Senescent Hepatocytes in Decompensated Liver Show Reduced UPRMT and Its Key Player, CLPP, Attenuates Senescence In Vitro.

Authors:  Bijoya Sen; Archana Rastogi; Rhisita Nath; Saggere M Shasthry; Viniyendra Pamecha; Sonika Pandey; Kapuganti Jagadis Gupta; Shiv K Sarin; Nirupma Trehanpati; Gayatri Ramakrishna
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2019-03-13

8.  Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study.

Authors:  Debashis Haldar; Barbara Kern; James Hodson; Matthew James Armstrong; Rene Adam; Gabriela Berlakovich; Josef Fritz; Benedikt Feurstein; Wolfgang Popp; Vincent Karam; Paolo Muiesan; John O'Grady; Neville Jamieson; Stephen J Wigmore; Jacques Pirenne; Seyed Ali Malek-Hosseini; Ernest Hidalgo; Yaman Tokat; Andreas Paul; Johann Pratschke; Michael Bartels; Pavel Trunecka; Utz Settmacher; Massimo Pinzani; Christophe Duvoux; Philip Noel Newsome; Stefan Schneeberger
Journal:  J Hepatol       Date:  2019-05-07       Impact factor: 25.083

9.  Diabetes and Hepatocellular Carcinoma: Incidence Trends and Impact of Liver Disease Etiology.

Authors:  Iliana Doycheva; Talan Zhang; Waseem Amjad; Paul J Thuluvath
Journal:  J Clin Exp Hepatol       Date:  2019-11-22

Review 10.  The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease.

Authors:  Hideki Fujii; Norifumi Kawada
Journal:  Int J Mol Sci       Date:  2020-05-29       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.